Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Ariel Fernandez Consultancy
Dehydrons are defects in protein structure that promote protein associations. Scientist Ariel Fernandez Stigliano recently showed that they are also endowed with chemical functionality, enabling and stimulating enzyme catalysis. The discovery may have paramount implications for biomedical engineering, catalysis optimization and epistructure-based drug design.
HOUSTON and BUENOS AIRES, Argentina, July 14, 2014 /PRNewswire/ -- Ariel Fernandez Consultancy serves the biotechnology industry by harnessing fundamental discoveries to broaden its technological base. In line with this goal, Ariel Fernandez in a recent Communication showed that a structural defect known as dehydron, causing interfacial tension in proteins, may also function as enabler and stimulator of enzyme catalysis. Thus, dehydrons functionalize the solvent for catalysis and also promote enzyme-substrate association. This dual role has paramount biotechnological implications for the design of structure-based enzyme agonists and inhibitors.
As described in the book Transformative Concepts for Drug Design: Target Wrapping (Ariel Fernandez, Springer, 2010), dehydrons are structural defects in soluble proteins known to promote protein associations. Recently, Ariel Fernandez ("dehydronic enzyme") has shown that dehydrons are also endowed with a chemical functionality, turning surrounding interfacial water into a chemical base. Thus, dehydrons activate nearby catalytic groups that perform a chemical (nucleophilic) attack on the substrate and, as they contribute to enzyme activation, they turn the local solvent into a better leaving group, promoting enzyme-substrate association. Thus, the dehydron behaves as a two-stroke molecular engine sustaining enzyme catalysis.
This discovery heralds the advent of novel molecular design based on "dehydron enablers-stimulators" that may be created or removed though designed alterations of the protein structure. On the other hand, novel drug-based enzyme inhibitors will emerge as the structural agonists are targeted through engineered protein-drug associations.
About Ariel Fernandez Consultancy
Ariel Fernandez Consultancy addresses scientific needs of the pharmaceutical industry, providing insights into drug design to broaden its technological base. The Consultancy seeks to provide the kind of thought leadership that translates into a competitive advantage, harnessing scientific knowledge to design prototypes with optimized safety and therapeutic potency.
For more information, visit: http://www.arielfernandez.net
Ariel Fernandez, Ph. D., CEO
Phone: 01154 11 4804 1711 (Buenos Aires, Argentina)
This release was issued through WebWire(R). For more information, visit http://www.webwire.com.
Press Release URL:
©2012 PR Newswire. All Rights Reserved.